Go to content
UR Home

Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial

Herrlinger, Ulrich ; Schäfer, Niklas ; Steinbach, Joachim P. ; Weyerbrock, Astrid ; Hau, Peter ; Goldbrunner, Roland ; Friedrich, Franziska ; Rohde, Veit ; Ringel, Florian ; Schlegel, Uwe ; Sabel, Michael ; Ronellenfitsch, Michael W. ; Uhl, Martin ; Maciaczyk, Jaroslaw ; Grau, Stefan ; Schnell, Oliver ; Hänel, Mathias ; Krex, Dietmar ; Vajkoczy, Peter ; Gerlach, Rüdiger ; Kortmann, Rolf-Dieter ; Mehdorn, Maximilian ; Tüttenberg, Jochen ; Mayer-Steinacker, Regine ; Fietkau, Rainer ; Brehmer, Stefanie ; Mack, Frederic ; Stuplich, Moritz ; Kebir, Sied ; Kohnen, Ralf ; Dunkl, Elmar ; Leutgeb, Barbara ; Proescholdt, Martin ; Pietsch, Torsten ; Urbach, Horst ; Belka, Claus ; Stummer, Walter ; Glas, Martin



Abstract

Purpose In patients with newly diagnosed glioblastoma that harbors a nonmethylated O-6-methylguanine-DNA methyltransferase promotor, standard temozolomide (TMZ) has, at best, limited efficacy. The GLARIUS trial thus explored bevacizumab plus irinotecan (BEV+IRI) as an alternative to TMZ. Patients and Methods In this phase II, unblinded trial 182 patients in 22 centers were randomly assigned 2: 1 ...

plus


Owner only: item control page
  1. Homepage UR

University Library

Publication Server

Contact:

Publishing: oa@ur.de

Dissertations: dissertationen@ur.de

Research data: daten@ur.de

Contact persons